

## Head And Neck Therapeutic and Disease Pipeline Review H2

Head And Neck Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, November 3, 2017 /EINPresswire.com/ -- Summary <u>Head and Neck</u> Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

## Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

GET SAMPLE REPORT @ <a href="https://www.wiseguyreports.com/sample-request/2450243-head-and-neck-cancer-pipeline-review-h2-2017">https://www.wiseguyreports.com/sample-request/2450243-head-and-neck-cancer-pipeline-review-h2-2017</a>

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 96, 115, 5, 85, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 7, 16 and 3 molecules, respectively.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology)

therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology)

## Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points

Table of Contents 2

Introduction 9

Head And Neck Cancer - Overview 10

Head And Neck Cancer - Therapeutics Development 11 Head And Neck Cancer - Therapeutics Assessment 54

Head And Neck Cancer - Companies Involved in Therapeutics Development 79

Head And Neck Cancer - Drug Profiles 166

Head And Neck Cancer - Dormant Projects 1402

Head And Neck Cancer - Discontinued Products 1413

Head And Neck Cancer - Product Development Milestones 1415

...Continued 🛚

ACCESS REPORT @ <a href="https://www.wiseguyreports.com/reports/2450243-head-and-neck-cancer-pipeline-review-h2-2017">https://www.wiseguyreports.com/reports/2450243-head-and-neck-cancer-pipeline-review-h2-2017</a>

Get in touch:

LinkedIn: <a href="https://www.linkedin.com/company/4828928">www.linkedin.com/company/4828928</a>
Twitter: <a href="https://twitter.com/WiseGuyReports">https://twitter.com/WiseGuyReports</a>

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.